Drug intelligence / Profile preview

AIG18

Development stage: Preclinical
Lead developer: AIGEN Sciences
Modality: Small Molecules
Administration: Oral

Overview

AIG18 is a small molecule inhibitor of METTL3 (methyltransferase-like 3), an enzyme that serves as the catalytic subunit of the m6A methyltransferase complex. Developed by AIGEN Sciences, AIG18 targets the epitranscriptomic regulation of RNA, specifically the N6-methyladenosine (m6A) modification, which plays a critical role in RNA stability, splicing, and translation. Dysregulation of METTL3 is associated with the progression of various malignancies. AIG18 is currently in early-stage preclinical development for the treatment of broad tumor types, aiming to suppress oncogenic signaling pathways by inhibiting m6A-mediated gene expression.

Other names: AIG18AIG-18AIG 18

Targets

METTL3 (Methyltransferase-like protein 3)

Beyond the preview

Go deeper on AIG18.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AIG18.

Explore the full profile